NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Diagnostics & Research · USD

Thermo Fisher Scientific Inc. (TMO) Stock Analysis

Thermo Fisher Scientific Inc. (TMO) is a Diagnostics & Research stock listed on NYSE and quoted in US Dollar.

TMO

$613.78

−$4.65 (−0.75%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TMO with… →

TMO Key Statistics

As of Sep 4, 2026
Trading
Open
$608.58
Previous Close
$618.43
Day's Range
605.53–615.74
52-Week Range
435.27–647.00
Volume
1.23M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.85
Valuation
Market Cap
$226.94B
P/E Ratio
33.00
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
22.30
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.84
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.90
EPS (ttm)Profit attributable to each share over the last twelve months.
18.60
Financials (FY)
Revenue (FY)
$44.56B+3.91%
Net Income (FY)
$6.70B+5.82%
Profit marginThe share of revenue left as profit after all costs and taxes.
15.04%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
369.75M
1-Year Return
+25.85%
Dividend and dates
Dividend
$1.88+0.30%
Ex-Dividend Date
September 15, 2026
Earnings Date
October 21, 2026estimated
Avg Volume
2.04M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

TMO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+6.14%
2025+11.78%
2024−1.72%
2023−3.36%
2022−17.29%
2021+43.54%
2020+43.72%
2019+45.55%
2018+18.21%
2017+35.03%
2016 (partial year)−9.67%

As of September 4, 2026.

TMO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$44.56B$6.70B15.0%
2024$42.88B$6.34B14.8%
2023$42.86B$6.00B14.0%
2022$44.92B$6.95B15.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$44.56B$18.24B$8.11B$6.70B15.0%
2024$42.88B$17.70B$7.72B$6.34B14.8%
2023$42.86B$17.10B$7.32B$6.00B14.0%
2022$44.92B$18.97B$8.51B$6.95B15.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

TMO Dividend History

$1.72+10.3% vs 2024

Dividends per share, 2025 · 4 payments

YearDividends per sharePaymentsChange
2026*$0.942—
2025$1.724+10.3%
2024$1.564+11.4%
2023$1.404+16.7%
YearDividends per sharePaymentsChange
2026 (partial year)$0.942—
2025$1.724+10.3%
2024$1.564+11.4%
2023$1.404+16.7%
2022$1.204+15.4%
2021$1.044+18.2%
2020$0.884+15.8%
2019$0.764+11.8%
2018$0.684+13.3%
2017$0.604+100.0%
2016$0.302—

Most recent payment: $0.47 per share, ex-dividend June 15, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

TMO Valuation vs Diagnostics & Research Median

Median of 49 stocks
MetricTMODiagnostics & Research medianvs median
P/E33.0033.080% below
P/S ratio4.904.992% below
Profit margin15.04%0.00%15.0 pts above

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Thermo Fisher Scientific Inc. (TMO) carries a market capitalisation of $226.94B. The company sits in the Healthcare sector, in the Diagnostics & Research industry. Headcount on file is 125,000.

Over the past 52 weeks the price has ranged from $435.27 to $647.00. TMO last closed at $613.78 on September 4, 2026. That is −$4.65 (−0.75%) against the previous close. The latest close sits 41.01% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $44.56B. Against the prior fiscal year total of $42.88B, that is a change of +3.91%. Net income for the same year was $6.70B. That is +5.82% against the prior fiscal year. The reported profit margin is 15.04%. That is 15 percentage points above the Diagnostics & Research median of 0%. Trailing earnings per share are 18.6.

Across the 4 fiscal years on file, revenue moves from $44.92B in 2022 to $44.56B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 33. That is 0.24% below the Diagnostics & Research median of 33.08. On forward earnings the ratio is 22.3. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.84. Measured against sales, the shares trade at 4.9 times revenue. On price-to-sales that is 1.85% below the Diagnostics & Research median of 4.99. 49 Diagnostics & Research companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 0.85. Daily returns over the trailing 10 years annualize to a volatility of 26.65%. Over the trailing twelve months the price has returned +25.85%. Across 10 years the annualized return works out at +15.37%.

Growth & Income

Shareholders receive a dividend, yielding 0.3% on the latest price. That is 0.5 percentage points below the Diagnostics & Research median yield of 0.76%. At the indicated rate that is $1.88 a share a year. The ex-dividend date on file is September 15, 2026. Dividends are recorded for 11 calendar years; 2026 shows 2 payments totalling $0.94 a share. The year before, 2025, totalled $1.72 a share.

The strongest complete calendar year on file is 2019 at +45.55%; the weakest is 2022 at −17.29%. Of the 9 complete calendar years on file, 6 finished higher. 2026 is still running; the price is +6.14% year to date.

Peer Comparison

Thermo Fisher Scientific Inc. (TMO) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Thermo Fisher Scientific Inc. TMO $226.94B 33.0
Danaher Corporation DHR $145.98B 37.0
Natera, Inc. NTRA $47.31B —
IQVIA Holdings Inc. IQV $44.07B 33.8

The Diagnostics & Research industry average P/E ratio is 33.1x. Thermo Fisher Scientific Inc. trades at a P/E of 33.0.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Diagnostics & Research Stocks

DHR

Danaher Corporation

$145.98B

 NTRA

Natera, Inc.

$47.31B

 IQV

IQVIA Holdings Inc.

$44.07B

 A

Agilent Technologies, Inc.

$42.54B

 IDXX

IDEXX Laboratories, Inc.

$42.18B

 WAT

Waters Corporation

$40.20B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Visit website →